Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$2.04 USD
+0.11 (5.70%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $2.04 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Earnings News For CHRS
-
Coherus BioSciences: Q4 Earnings Snapshot
-
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
-
Coherus BioSciences: Q3 Earnings Snapshot
-
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
-
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
-
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
-
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
-
Coherus BioSciences: Q1 Earnings Snapshot
-
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
-
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
-
Coherus BioSciences: Q4 Earnings Snapshot
-
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
-
Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates
-
Coherus BioSciences: Q3 Earnings Snapshot
-
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
-
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
-
Coherus BioSciences: Q2 Earnings Snapshot
-
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
-
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
-
Coherus BioSciences (CHRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Coherus BioSciences (CHRS) Reports Q4 Loss, Misses Revenue Estimates
-
Coherus BioSciences (CHRS) Reports Q3 Loss, Misses Revenue Estimates
-
Earnings Preview: Coherus BioSciences (CHRS) Q3 Earnings Expected to Decline
-
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
-
Analysts Estimate Coherus BioSciences (CHRS) to Report a Decline in Earnings: What to Look Out for